The dip is the lowest the pharmaceutical company has seen in 14 years.
The trial would have been the foundation for expanding treatment use of Opdivo. However, the drug did not reach its goal of extending progression-free survival for untreated patients with advanced non-small cell lung cancer as hoped.
Stocks were down 16 percent to $63.05 at 12:03 p.m. Friday. Merck — the producer of Opdivo’s No. 1 competitor, Keytruda, — stock rose 6.9 percent. Bristol-Myer’s other competitors AstraZeneca and Roche Holding stock rose 1.2 percent and 2.2 percent, respectively.
Analysts have said Bristol-Myers’ immune treatments Opdivo and Yervoy (a metastatic melanoma treatment) will account for half of Bristol-Myers sales by 2020. The treatments grew Bristol-Myers’s U.S. revenue 46 percent in the second quarter this year.
Overall, Opdivo saw a sixfold increase in quarterly sales to $840 million this year. The drug brought in $942 million last year, which is predicted to escalate to $7.7 billion by 2018.
More articles about supply chain:
CVS scraps coverage of 2 brand-name biotech drugs for biosimilars
Drug company drives $48k brain-eating amoeba treatment to SC hospital
Transforming data into insights that drive better outcomes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
